Arisaph Pharmaceuticals receives STTR grants to build up cancer drug candidates Arisaph Pharmaceuticals, Inc., a privately held biopharmaceutical organization focused on advancement and discovery of novel treatments for cardiometabolic diseases and cancer, announced today that it’s been awarded a stage II SMALL COMPANY Technology Transfer grant and a supplemental phase I grant, both from the National Cancer Institute of the National Institutes of Health. The phase II award of $1,066,916 supports research and development for the Company's tumor-activated prodrug system for the treating a number of cancers sildenafil prix http://pharmaciecambier.com . The supplemental stage I award of $160,721 funds extra preclinical studies of the Company's small-molecule immune modulators for the stimulation of tumor immunity following treatment with BRAF inhibitors in melanoma.
‘SUDC is a brand-new name for SIDS,’ wrote one KXAN.com commenter. ‘This is what you get when you lay your baby on a mattress of fire retardant and anti-microbial chemical substances, and practice the present day day equivalent of witchcraft by injecting your child with 34 vaccines by 36 months.’ A scholarly study published in the peer-examined journal Current Medication and Chemistry, entitled ‘Sudden infant loss of life following hexavalent vaccination: a neuropathologic research,’ also found that SIDS occurs mostly after infants receive their primary span of vaccinations. SIDS may also occur beyond twelve months old when children remain being jabbed with other vaccines on the routine.. Are vaccines to blame for Sudden Unexplained Death in Childhood? A Texas couple is struggling to make sense of their 14-month-old son’s recent death, one of the latest cases of a mystery condition that the medical program is now referring to as ‘Sudden Unexplained Death in Childhood,’ or SUDC.